Postoperative Lymphatic Exudate is a Proximal Source of ctDNA and Detects Recurrence in HPV-negative Head and Neck Cancer

Seka Lazare[1], Zhuosheng Gu[1], Noah Earland[2], Adam Harmon[1], Maciej Pacula[1], Megan Long[1], Ashley Tellis[1], Damion Whitfield[1], Adam Benson[1], Sophie Gerndt[3], Peter Harris[2], Lucien Khalil[4], Ricardo Ramirez[5], Zhongping Xu[3], Benjamin Wahle[5], Sid Puram[5], Doug Adkins[6], Wade Thorstad[7], Daniel Zandberg[8,9], Rebecca Chernock[10], Heath Skinner[9,11], Raja Seethala[9,12], Robert L. Ferris[3,9], Marra S. Francis[1], Wendy Winckler[1], Aadel A. Chaudhuri[13,14,15], Jose P. Zevallos[9,16]

[1]Droplet Biosciences, Inc.
[2]Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
[3]Division of Otolaryngology-Head and Neck Surgery, Allegheny Health Network, Pittsburgh, Pennsylvania.
[4]Pittsburgh Medical Center, Pittsburgh, Pennsylvania
[5]Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri.
[6]Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
[7]Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
[8]Division of Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, St. Louis, Missouri
[9]UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
[10]Department of Pathology, Washington University School of Medicine, St. Louis, Missouri.
[11]Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
[12]Department of Pathology University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
[13]Department of Computer Science and Engineering, Washington University, St. Louis, Missouri
[14]Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
[15]Department of Immunology, Mayo Clinic, Rochester, Minnesota
[16]Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

ABSTRACT

Relapse is a major cause of failure after surgery in HPV-human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC),), with up to 50% of patients recurring within 2 years. While clinicopathologic criteria exist for adjuvant treatment, these criteria are imprecise and have not changed for decades. However, no reliable method exists to tailor adjuvant therapy for individual patients based on risk of recurrence after surgery. Using an ultra-sensitive targeted sequencing approach, we demonstrate that circulating tumor DNA (ctDNA) in lymphatic exudate collected via surgical drains ("lymph") 24 hours after surgery accurately identifies MRD and outperforms plasma in an initial cohort of 36 HNSCC patients. We then applied the lymph ctDNA test to an independent, multi-site cohort of 37 HNSCC patients, replicating the original finding. Lymph performance was particularly enhanced in locoregional relapse in both cohorts and generalized to early stage (I-II)

patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence. We demonstrate a liquid biopsy approach using a historically overlooked biofluid to potentially enable precision adjuvant therapy and achieve superior oncologic outcomes.

SIGNIFICANCE

Postoperative lymphatic exudate represents a novel proximal analyte for MRD detection in HPV- HNSCC designed specifically for use in the immediate post-surgical window when adjuvant therapy decisions must be made. Accurate MRD identification at this early timepoint has potential to augment traditional pathology and personalize adjuvant treatment paradigms in HPV-negative HNSCC.

INTRODUCTION

The incidence of HNSCC continues to increase worldwide and is currently the sixth most common cancer [1]. While treatment selection considers pathological risk factors such as HPV status, tumor stage or extranodal extension (ENE), 5-year overall survival rates remain low (10-61%, depending on HNSCC subtype and stage) [2,3]. Treatment approaches such as aggressive adjuvant radiotherapy (RT) or chemotherapy plus radiotherapy (CRT) have been associated with improvements in both progression free survival (PFS) and overall survival (OS) in HNSCC patients, but often result in high morbidity, as well as physiological, financial and emotional burden [4–6].

There is a critical need to improve treatment selection criteria for patients with HNSCC, improve oncologic outcomes, and limit unnecessary treatment morbidity. While clinicopathologic criteria exist for offering adjuvant radiotherapy or chemoradiation postoperatively for high-risk patients, these criteria are imprecise and have been unchanged for at least 3 decades [3]. Liquid biopsy, particularly cell-free DNA (cfDNA) based diagnostics, has shown clinical utility for guiding treatment and detecting MRD in lung, breast and colorectal cancers [7–9]. In HNSCC, longitudinal plasma ctDNA detection has been shown to precede clinical recurrence by imaging [10,11]. Clinical use of longitudinal plasma ctDNA is typically employed in a surveillance setting, i.e. to monitor adjuvant treatment response or detect emerging resistance mutations [12]. While serial plasma testing achieves high MRD sensitivity over time, these tests typically are not administered until at least 1-3 months after surgery [13,14]. ctDNA is poorly represented in plasma in the earliest days after surgery [7], limiting its utility to aid in adjuvant treatment decisions.

Given the limitations of plasma-based MRD testing, there has been interest in examining more proximal biofluids, including urine, bronchioalveolar lavage fluid, CSF, etc. Tumor proximal biofluids have shown increased sensitivity compared to plasma across multiple cancer types [15–17]. Our group has pioneered the use of surgical effluent, collected from routinely placed surgical drains, as a novel proximal biofluid. This “lymph” fluid is a mixture of blood, lymphatic exudate, and interstitial fluid, but by 24 hours after surgery, tends to be more lymphatic and interstitial than sanguineous (Fig 1B). The lymphatic system plays a critical role in the tumor microenvironment and is the primary route of metastatic spread [18,19], making it an ideal, but to-date largely unexplored, biospecimen to evaluate early MRD. Previous work from our group demonstrated that detection of HPV viral DNA in surgical lymphatic fluid is prognostic in surgically-treated HPV-positive HNSCC [20].

In this study we present a novel and generalizable method for measuring postoperative MRD in HPV-negative HNSCC using lymph ctDNA. Using a tumor-informed, ultra-deep sequencing approach, we demonstrate that lymph ctDNA is more prognostic of recurrence than clinicopathologic features alone and superior to plasma ctDNA from the same timepoint. Our approach overcomes the major limitations of plasma-based MRD assays by measuring proximally to the site of tumor early enough to make adjuvant therapy decisions. The results of this study provide the foundation for interventional clinical trials in HPV-negative HNSCC that use lymph ctDNA in conjunction with pathology to precisely stratify escalation of adjuvant therapy in high-risk patients.

RESULTS

Study Population

76 HPV-negative HNSCC patients were initially included in the study (Fig 1A). One patient was excluded due to a blood sample mismatch and two patients were excluded because tumor samples failed sequencing, resulting in a total study population of 73 patients. Of the 73 patients, 36 patients were studied in an initial cohort and 37 were reserved for the replication cohort. There was no significant difference between the initial and replication cohorts for available clinical data (STables 1-4). The median age of the study population was 63. Forty-nine (67%) were male and 52 (71.2%) patients received adjuvant therapy (1.4% CT, 46.6% RT, 20.5% CRT, 2.7% immunotherapy). The median follow up was 15.7 months. Thirty-one out of 73 patients experienced disease recurrence (REC) (16 initial cohort and 15 replication cohort) (Fig 4A) and 42 out of 73 patients had no evidence of disease (NED) (20 initial and 22 replication cohort) (Fig 4B). Forty-two patients had matched plasma samples available (29 initial cohort,13 replication cohort).

Lymph and Plasma sample composition at 24 hours post-surgery

Lymph collected via surgical drains represents a novel biofluid with distinct characteristics compared to plasma. To evaluate the composition of postoperative lymphatic exudate at 24 hours, we assayed 3 proteins (ANXA1, ARG1, and S100A4) reported to be abundant in lymphatic fluid aspirated directly from the cisterna chyli but undetectable in patient-matched plasma [21]. We observe a strongly significant enrichment ($P < 10^{-11}$) of all 3 lymph-associated proteins in 24-hour postoperative lymphatic exudate compared to plasma (Fig 1C), suggesting that this biofluid has a meaningful lymphatic component.

We also observe distinct cfDNA characteristics in postoperative lymph. cfDNA in lymph was 65 times more concentrated than plasma (mean 4.14 ng per μL of lymph,

mean 0.06 ng per μL plasma, $P < 0.001$) (Fig 1D.) Additionally, lymph cfDNA displays a distinct nucleosome distribution and a higher dinucleosome fraction compared to plasma (SFig 1A). The mean ctDNA allelic fraction was 2 times higher in lymph than in plasma samples (lymph = 0.004 ± 0.036%; plasma = 0.002 ± 0.078%; $P = 0.03$, n = 42) (FIG 1E). Taken together, lymph represents a differentiated, novel biofluid with substantially higher ctDNA content than plasma.

Lymph but not Plasma ctDNA Correlates with HNSCC Recurrence

To maximize sensitivity and specificity, we employed a tumor-informed, deep coverage next-generation sequencing assay capable of routine variant detection down to 1:100,000 (SFig 1L). All analytes were sequenced using a custom 699-gene panel comprised of the most frequently mutated genes in HPV-negative HNSCC [22]. Tumor and whole blood libraries were sequenced to a median of 533x deduplicated coverage (range 249x - 2709x). Lymph and plasma cfDNA libraries were sequenced to a median of 6322x deduplicated coverage (range 2544x - 13675x). Patient-specific somatic variants (median 9, range 2 - 95) detected in tumor were directly genotyped to examine those positions in lymph and plasma. A sample was classified as positive if the mean ctDNA variant allele fraction (VAF) exceeded the calibrated MRD cut-off (see Methods).

We performed survival analysis using the determined MRD status from both lymph and plasma samples from the initial study cohort. We found that lymph ctDNA could accurately identify HNSCC recurrence (sensitivity = 75%, specificity = 60%; $P = 0.03$) (FIG 2A). The hazard ratio (HR) for disease recurrence in lymph ctDNA+ patients was 3.3, indicating that disease recurrence was more than 3 times more likely among patients with detectable lymph ctDNA than among those without during

the follow-up period. We next attempted to replicate these results in an independent cohort of 37 patients. Again, lymph ctDNA positivity accurately identified HNSCC recurrence (sensitivity = 67%, specificity = 68%; *P* = 0.05, HR = 2.8) (FIG 2B), suggesting that lymph profiling is a reproducible approach to detect MRD 24 hours after surgery.

To evaluate the potential benefit of a proximal fluid on local relapse patterns, we next compared patients with locoregional relapse and NED patients in both the initial and replication cohorts. Detection of ctDNA in lymph was strongly associated with recurrence in both cohorts (Cohort 1: n = 31, sensitivity = 82%, specificity = 60%; *P* = 0.025, HR = 4.9; Cohort 2: n = 31, sensitivity = 78%, specificity = 68%; *P* = 0.022, HR = 5.2) (Fig 2C and 2D). The reproducible enhanced sensitivity for locoregional recurrence observed in these cohorts is consistent with the hypothesis that a proximal fluid will be enriched for tumor-associated analytes in the setting of local tumor growth.

Forty-two of the patients across these cohorts had matched plasma drawn 24 hours after surgery. Applying the same sensitive NGS approach used for lymph, plasma was not predictive of MRD at this timepoint (sensitivity = 33%, specificity = 70%; *P* = 0.8, HR = 1.1; positive predictive value (PPV) = 38%, negative predictive value (NPV) = 66%) (Fig 2E). Lymph correctly identified MRD twice as often in the matched cohort (sensitivity = 67%, specificity = 67%; p = 0.02, HR = 3.2; PPV = 53%, NPV = 78%). Plasma ctDNA performed worse in locoregional disease (n = 34, sensitivity = 29%, specificity = 70%; *P* = 0.95, HR = 0.95) (SFig 1C), as has been previously reported [7].

Lymph ctDNA outperforms individual pathology features and shows synergy in a combination model

We compared relevant clinical features (e.g. ENE status, tumor stage, etc.) between our two cohorts and demonstrated no significant differences between these populations (Supplementary Table 4). Having established their equivalence, we then pooled the cohorts into a single 73 patient group to better power subgroup analyses. In aggregate, lymph ctDNA in the pooled cohort demonstrated 71% sensitivity and 64% specificity to detect HNSCC recurrence (*P* = 0.003, HR = 3.08) (Fig 3C). Multivariate Cox regression analysis was performed with lymph ctDNA status and relevant clinical features for PFS (STable 5). Only lymph ctDNA status and positive lymph nodes (LN) had significant *P* values, indicating minimal confounding effects for lymph ctDNA due to clinical features. A similar lack of confounding effects was observed for OS (SFig 1J and STable 6).

We then sought to understand the prognostic value of lymph ctDNA compared to individual high-risk pathologic features (ENE, positive LN, perineural invasion, and lymphovascular invasion (LVI)). While two of these pathology features (positive LN and LVI) were statistically associated with disease recurrence in this cohort, each was less prognostic of recurrence than lymph ctDNA (HR 0.95-2.31 vs. 3.08) (SFig 1D-I). A simple logistic regression model combining all 4 pathology features was significantly associated with recurrence (sensitivity = 42%, specificity = 81%; p = 0.02, HR = 2.37) but still underperformed compared to lymph ctDNA (sensitivity = 71%, specificity = 64%, *P* = 0.003, HR = 3.1) (Fig 3D).

A differentiating feature of a lymph-based MRD approach is that results could be available shortly after surgery and in the same timeframe as surgical pathology.

Therefore, we sought to determine how lymph ctDNA interacts with high-risk pathology feature classification by using a logistic regression model, incorporating the 4 high-risk pathologic features examined above plus lymph ctDNA. When lymph ctDNA was considered alongside pathology features, recurrence detection was improved compared to pathology or lymph ctDNA status alone (sensitivity = 84%, specificity = 52%; $P = 0.002$, HR = 4.09), indicating synergy between pathologic and molecular features (Fig 3D).

We next sought to determine the prognostic value of lymph ctDNA in pathologically low-risk patients, including N0 patients and patients without ENE. Lymph ctDNA performs equally well in the N0 population as in the full cohort ($P = 0.11$, HR = 3.39), suggesting lymph ctDNA detection may be a relevant biomarker in earlier stage patients (Fig 3A). Furthermore, lymph ctDNA is strongly associated with recurrence in patients without ENE (sensitivity = 79%, specificity = 65%; $P = 0.003$, HR = 4.6) (Fig 3B), demonstrating that lymph ctDNA can identify patients at higher risk of recurrence despite their having lower risk pathology.

Potential Predictive Applications of Lymph ctDNA

HNSCC patients treated with primary surgical resection are stratified to no adjuvant therapy, adjuvant RT, or adjuvant CRT based on their pathologic features. Within the limitations of a retrospective, observational cohort, we sought to determine whether lymph ctDNA was prognostic in patients who did not receive maximal therapy (either no adjuvant or RT alone). We demonstrate that lymph ctDNA is significantly associated with recurrence in patients who did not receive CRT ($P = 0.01$) (Fig 3E), suggesting that there is opportunity to further stratify this group of patients for treatment escalation using molecular testing. In contrast, there was no significant

difference in PFS by lymph ctDNA for patients receiving maximal CRT (P = 0.20) (Fig 3F). Taken together, these findings provide rationale for future interventional studies incorporating lymph ctDNA status into adjuvant decisions for HPV- HNSCC patients undergoing surgery.

To illustrate the potential utility of lymph ctDNA testing to impact clinical care, we present two case studies that focus on patients with pathologically intermediate-risk disease who underwent curative-intent tumor resection surgery. Patient DF067 (Fig. 4C) was T2N0M0 with LVI and received 70 Gy of adjuvant RT but no chemotherapy. One day after surgery, postoperative lymph was positive for ctDNA. Thirteen months later, DF067 suffered a locoregional recurrence in the right palate.

Patient DF108 (Fig. 4D) was T4N0M0 with no evidence of other high risk pathological features and received 60 Gy adjuvant RT but no chemotherapy. The 24-hour lymph sample was positive for ctDNA while the 24-hour plasma sample was negative. Six months after surgery, the patient recurred distantly in the right lung. In both cases, postoperative lymph ctDNA tests were consistent with eventual relapse. These data illustrate that some patients with low-risk pathology will still experience relapses that pathology alone cannot predict but are detectable at the molecular level. Lymph ctDNA represents a novel and complementary facet to relapse risk prediction that in the future could be used as an adjunct to pathology to better tailor adjuvant therapy selection.

DISCUSSION

Our work is the first to establish the potential utility of surgical lymphatic exudate as a proximal bioanalyte for measuring MRD for use in adjuvant therapy decision-making in the management of HPV-negative HNSCC. We demonstrate that lymph has a 65-

fold higher cfDNA yield per mL and a 2x higher tumor allelic fraction than time-matched plasma. With a 130-fold advantage in available tumor-derived DNA, lymph ctDNA tests could disproportionately benefit from emerging ultra-sensitive NGS methods with <0.0001% VAF detection and beyond. The fundamental properties of lymph have the potential to overcome the sensitivity challenges faced by plasma testing in the immediate postoperative setting.

In our initial cohort, we found that lymph ctDNA was significantly associated with recurrence detection, findings that then replicated in an independent multi-site cohort. Strikingly, lymph ctDNA accurately identified HNSCC recurrence with a sensitivity of 71% and a specificity of 64% ($P < 0.003$) in the full cohort, whereas plasma was not significant at this timepoint with a sensitivity of only 33%, identifying MRD in less than half as many patients.

Plasma-based MRD assays have historically struggled to detect locoregional recurrence [23]. Our results suggest that lymph effectively overcomes this difficulty. Local recurrence within 1 year was 5 times more likely among patients with ctDNA-positive lymph samples than among those with ctDNA-negative lymph samples. Accurate MRD identification in patients with locoregional disease suggests that postoperative lymph analysis may have the potential to detect residual cancer before it spreads beyond the original tumor site and adjacent lymph nodes.

We also observe that lymph outperforms individual high-risk pathology features or a combination of them at predicting recurrence. Lymph ctDNA correlates with recurrence in patients with low and intermediate-risk pathology features such as ENE-negative disease with a sensitivity of 71% and a specificity of 64% ($p < 0.003$). This suggests that a molecular test has potential to further stratify recurrence risk.

When combined, lymph and a model of four high-risk pathology features synergize to outperform pathology or lymph alone. Given the 24-hour sampling, lymph ctDNA test results could be reported <2 weeks after surgery, on a similar time scale to traditional pathology reports. This combination of synergy and synchronous timing indicates that postoperative lymph testing could enable MRD findings to be used in concert with traditional pathology measures to provide more accurate, personalized adjuvant treatment decisions and be readily incorporated into multidisciplinary tumor board discussions.

The results of this study highlight the potential value of lymph ctDNA testing over plasma in the early postoperative period, but the temporary nature of surgical drains limits longitudinal surveillance using this approach alone. MRD detection using lymph and plasma can be complementary: for example, an initial lymph test 24 hours after surgery to enable sensitive MRD results in time to inform adjuvant therapy decisions plus longitudinal plasma (or other renewable biofluid) testing to monitor patient response on therapy and identify recurrence at later timepoints.

An important limitation of the current work is that as an observational study, no patients were treated based on their lymph ctDNA results. Therefore, specificity is likely underestimated in both lymph and plasma given that samples were collected prior to adjuvant therapy. 11 out of 15 misclassified lymph ctDNA+ NED patients received adjuvant therapy. Reported RT and CRT response rates would suggest that some of these apparent “false positives” at 24 hours were in fact patients who responded to subsequent adjuvant treatment and therefore had favorable outcomes despite having MRD after surgery. This hypothesis can be tested in future clinical trials.

In this cohort, we see that lymph ctDNA is prognostic of PFS in patients who did not receive maximum adjuvant therapy (CRT). This, combined with accurate MRD detection in patients with lower-risk pathologic features, provides proof-of-principle that postoperative lymph MRD testing has the potential to stratify patients to receive more personalized adjuvant treatment. Clinical trials have demonstrated that escalating treatment from RT to CRT can improve median OS by 3.3 years [3], but the addition of chemotherapy comes with significant treatment morbidities [24]. A treatment stratification paradigm incorporating lymph ctDNA testing could help improve outcomes and limit overtreatment by targeting therapy to those most at risk of relapse. The next step to demonstrate the utility of the lymph ctDNA approach is validation in interventional clinical trials. This may include, for instance, patients with intermediate pathologic risk who are stratified to escalated adjuvant therapy based on a positive lymph ctDNA result.

In conclusion, we introduce postoperative lymph ctDNA as a novel, proximal, and early source to detect MRD with the potential to be incorporated into adjuvant therapy decision-making. Advances in liquid biopsy technology may allow a biofluid that has been largely overlooked for decades to enable precision adjuvant therapy and achieve the best oncologic outcomes possible.

PATIENTS AND METHODS (Fig 1A)

Details on Study Design, Ethical Approval and Sample Collection, Processing, DNA extraction and proteomic analysis can be found in the supplementary method section.

Next-generation Sequencing

Genomic DNA was fragmented to 150 bp with the Covaris ME220. 80 ng of cfDNA or 200 ng of genomic DNA was prepared using the xGen cfDNA and FFPE Library

preparation kit (Integrated DNA Technologies, Coralville, IA). 600 ng of prepared library was used for hybridization using a custom hybridization panel and standard hybridization reagent kit (Twist Bioscience, San Francisco, CA). Pre-hybridized and hybridized libraries were assessed using DS1000 DNA Screentape (Agilent Technologies, Santa Clara, CA) and quantified using Qubit HS dsDNA Assay (Thermo Fisher Scientific, Waltham, MA).

Hybridized libraries were sequenced on NovaSeq 6000 (Illumina, San Diego, CA).

Tumor-informed Variant Calling

Raw reads were demultiplexed using BCL Convert (Illumina, San Diego, CA). Sample matching was performed with a custom pipeline using allele fractions of known single-nucleotide polymorphisms (SNPs) to identify samples from the same individual. Consensus read calling and alignment of reads with UMI family size over 2 were performed as previously described [20].

Tumor variant calling was performed as previously published [20]. A panel of normals was created with 50 whole blood samples following GATK best practices. From these variants, somatic mutations on coding sequences were identified using Ensembl Variant Effect Predictor annotation. Somatic mutations with depth <50x or VAF <5% were excluded. Somatic mutations on sex chromosomes were also excluded. Matched whole blood samples were used to filter out germline mutations or mutations driven by clonal hematopoiesis. All remaining somatic mutations positions identified in tumors were directly genotyped in matched lymph and plasma samples. A base-specific error model (BEM) was estimated at each somatic mutation position to quantify the background noise for single nucleotide variants (SNVs). Each model for lymph was built using 91 high-quality lymph samples sequenced to median

of 6328x coverage, ranging from 2544x to 11580x, while model for plasma was built using 49 plasma samples sequenced to median of 6191x coverage, ranging from 2911x to 13675x. BEM was fit by Weibull distribution if more than 5 non-zero non-reference alleles were observed at a tumor variant position across the reference samples. Otherwise, Gaussian distribution was used to fit BEM. For each model, BEM cutoff was defined as 75th percentile of the distribution. For indels, the cutoff was defined as 0.1%. Variant allele fraction was set to 0 if the VAF was not greater than BEM cutoff. Mean VAF was calculated for each lymph and plasma sample using all somatic mutations passed filtering in the tumor of the patient.

Data Analysis

Python 3.8.10 was used for all downstream analyses. Mann-Whitney U test was used for group comparisons between lymph and plasma samples, and comparisons between REC and NED patients. A calibrated MRD cutoff (C) was estimated for each lymph or plasma sample based on its sequencing depth and somatic mutation count in corresponding tumor sample. cfDNA samples with mean VAF greater than the cutoff were called as MRD positive, and those that did not were predicted as MRD negative. Further details on calibrated MRD cut off can be found in the supplementary methods section.

Following binary prediction by the models, the Kaplan-Meier estimator with log-rank test and Cox proportional-hazards model were used for survival analysis. For clinical features, missing values were imputed by most frequent values except for tumor size where median was used. Immunotherapy was removed from analysis for OS due to unbalanced stratification. Sensitivity and specificity were calculated based on disease progression status respectively. Mann-Whitney U test and Wilcoxon signed-

rank test were used for group comparison. Student's t-test, Fisher's exact test, and Spearman's rank correlation coefficient were used to rule out confounding effects by clinical and pathological features.

ACKNOWLEDGEMENTS

The authors thank Jillian Lokere, MS for editorial assistance in preparing the manuscript, Katie Campbell for helpful feedback on the manuscript, and Veronica Falconieri Hays for illustration assistance on Figure 1A.

REFERENCES

1. Bray, F. *et al.* Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* **74**, 229–263 (2024).
2. Machiels, J.-P. *et al.* Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann. Oncol.* **31**, 1462–1475 (2020).
3. Bernier, J. *et al.* Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. *N. Engl. J. Med.* **350**, 1945–1952 (2004).
4. Tsai, C.-J. *et al.* Adjuvant Radiotherapy Significantly Increases Neck Control and Survival in Early Oral Cancer Patients with Solitary Nodal Involvement: A National Cancer Registry Database Analysis. *Cancers* **13**, 3742 (2021).
5. Lacas, B. *et al.* Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. *Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol.* **156**, 281–293 (2021).
6. Tasoulas, J. *et al.* The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC. *Cancer Med.* **10**, 3231–3239 (2021).
7. Tie, J. *et al.* Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. *N. Engl. J. Med.* **386**, 2261–2272 (2022).
8. Bratman, S. V. *et al.* Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. *Nat. Cancer* **1**, 873–881 (2020).

9. Leighl, N. B. *et al.* Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer. *Clin. Cancer Res.* **25**, 4691–4700 (2019).
10. Flach, S. *et al.* Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. *Br. J. Cancer* **126**, 1186–1195 (2022).
11. Huang, X. *et al.* Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma. *J. Biomed. Sci.* **30**, 65 (2023).
12. Fribbens, C. *et al.* Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer. *J. Clin. Oncol.* **34**, 2961–2968 (2016).
13. Hanna, G. J. *et al.* Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma. *Clin. Cancer Res.* **30**, 3329–3336 (2024).
14. Liu, G. *et al.* Clinical validation of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies. *Ann. Oncol.* **0**, (2024).
15. Cui, Y. *et al.* Longitudinal detection of somatic mutations in saliva and plasma for the surveillance of oral squamous cell carcinomas. *PLOS ONE* **16**, e0256979 (2021).
16. Chauhan, P. S. *et al.* Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients. *Npj Precis. Oncol.* **7**, 1–6 (2023).
17. Nair, V. S. *et al.* Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. *Cancer Res.* **82**, 2838–2847 (2022).
18. Ji, H. *et al.* Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. *Signal Transduct. Target. Ther.* **8**, 1–33 (2023).

19. Delclaux, I., Ventre, K. S., Jones, D. & Lund, A. W. The tumor-draining lymph node as a reservoir for systemic immune surveillance. *Trends Cancer* **10**, 28–37 (2024).
20. Earland, N. *et al.* Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer. *Clin. Cancer Res.* **30**, 1409–1421 (2024).
21. Dzieciatkowska, M. *et al.* Lymph Is Not a Plasma Ultrafiltrate: A Proteomic Analysis of Injured Patients. *Shock* **42**, 485 (2014).
22. Lawrence, M. S. *et al.* Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* **517**, 576–582 (2015).
23. Tie, J. *et al.* Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. *Int. J. Cancer* **148**, 1014–1026 (2021).
24. Tengku, S. *et al.* Late-onset swallowing outcomes post-treatment for head and neck cancer in a UK-based population. *J. Laryngol. Otol.* **137**, 293–300.
25. Lu, H.-J. *et al.* Clinical, pathophysiologic, and genomic analysis of the outcomes of primary head and neck malignancy after pulmonary metastasectomy. *Sci. Rep.* **9**, 12913 (2019).

Figure 1



Figure 1 24-hour post-operative lymph is enriched in ctDNA. **A.** Graphical method description. **B.** Representative surgical effluent collected via surgical drains at 8-, 16- and 24-hours post-surgery (n=3 patients). **C.** ANXA1, ARG1 and S100A4 protein expression in lymph and plasma (*P* values 1.8 x 10-12, 5.8 x 10-11, and 3.5 x 10-12, respectively, n = 41, 36, and 41 respectively). **D.** Higher cfDNA content (ng per µL) of lymph compared to plasma (n=42 patients). **E.** Average variant allele frequency of ctDNA mutations in lymph vs plasma sequenced libraries (n=42).

Figure 2



Figure 2 Lymph but not plasma ctDNA correlates with HNSCC recurrence **A.** KM PFS Analysis by Lymph ctDNA status in Initial Cohort patients (n=36), sensitivity = 75%, specificity = 60%; Logrank *P* = 0.03, HR = 3.3 (95% CI: 1.1-10.3, *P* = 0.04). **B**. KM PFS Analysis by lymph ctDNA Status in Replication Cohort patients (n=37), sensitivity = 67%, specificity = 68%; Logrank *P* = 0.05, HR = 2.8 (95% CI: 1.0-8.1, *P* = 0.06). **C.** KM PFS Analysis by lymph ctDNA for locoregional recurred and NED patients in Initial Cohort (n=31), sensitivity = 82%, specificity = 60%; Logrank *P* = 0.02, HR = 4.9 (95% CI: 1.0-22.8, *P* = 0.04). **D.** KM PFS Analysis by lymph ctDNA for locoregional recurred and NED patients in Replication Cohort (n=31), sensitivity = 78%, specificity = 68%; Logrank *P* = 0.02, HR = 5.2 (95% CI: 1.1-25.2, *P* = 0.04). **E.** KM PFS analysis by lymph compared to plasma ctDNA status in matched patients (n=42), lymph sensitivity = 67%, specificity = 67%; Logrank *P* = 0.02, HR = 3.2 (95% CI: 1.1-9.4, *P* = 0.03); plasma sensitivity = 33%, specificity = 70%; Logrank *P* = 0.82, HR = 1.1 (95% CI: 0.4-3.3, *P* = 0.82).

Figure 3



Figure 3 Lymph outperforms high-risk pathology features. **A.** KM PFS analysis by lymph ctDNA status in N0 stage patient (n=27), sensitivity = 75%, specificity = 58%, Logrank p = 0.11, HR = 3.4 (95% CI: 0.7-16.8, *P* = 0.14). **B.** KM PFS analysis by lymph ctDNA status in ENE-negative patients (n=50), sensitivity = 79%, specificity = 65%, Logrank *P* = 0.003, HR = 4.6 (95% CI: 1.5-13.9, *P* = 0.01). **C.** KM PFS analysis of combined cohort by lymph ctDNA status (n=73), sensitivity = 71%, specificity = 64%, Logrank P = 0.003, HR = 3.1 (95% CI: 1.4-6.7, *P* < 0.005). **D.** KM PFS analysis stratified by pathology, sensitivity = 42%, specificity = 81%, Logrank *P* = 0.02, HR = 2.4 (95% CI: 1.2-4.9, P = 0.02) and lymph ctDNA + pathology status, sensitivity = 84%, specificity = 52%, Logrank *P* = 0.002, HR = 4.1 (95% CI: 1.6-10.7, *P* < 0.005) for combined cohort (n=73). **E.** KM PFS analysis by lymph ctDNA status in patients who did not receive adjuvant therapy or received radiotherapy (n=54), sensitivity = 71%, specificity = 63%, Logrank *P* = 0.01, HR = 3.0 (95% CI: 1.2-7.2, *P* = 0.02). **F.** KM PFS analysis by lymph ctDNA status in patients who received adjuvant radiotherapy and chemotherapy (n=15), sensitivity = 67%, specificity = 67%, Logrank *P* = 0.18, HR = 3.1 (95% CI: 0.6-17.2, *P* = 0.2).

Figure 4



Figure 4 Lymph ctDNA can inform adjuvant treatment decision-making. **A.** Swimmer plot of recurred patients by patient ID (n=31) describing lymph ctDNA status, treatment course, recurrence type and outcome. **B.** Swimmer plot of non-recurred patients by patient ID (n=42) describing lymph ctDNA status, treatment course, recurrence type and outcome. **C.** Clinical vignette of patient DF067 with positive lymph ctDNA. Patient received 70 Gy of adjuvant RT but no chemotherapy. Patient experienced locoregional recurrence in the right palate 13 months later. **D.** Clinical vignette of intermediate-risk patient DF108 with T4N0M0 oral HNSCC, who was managed with radiotherapy. Lymph ctDNA was positive but plasma ctDNA was not. Patient experienced distant recurrence (lung) 6 months after surgery. Representative lung CT image shown as previously published [25].